Values First Advisors Inc. Invests $293,000 in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Values First Advisors Inc. bought a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 7,399 shares of the biopharmaceutical company’s stock, valued at approximately $293,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Point72 Hong Kong Ltd grew its position in Celldex Therapeutics by 57.9% during the first quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 511 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in Celldex Therapeutics by 70.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 805 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Celldex Therapeutics by 604.9% in the first quarter. Tower Research Capital LLC TRC now owns 2,178 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 1,869 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Celldex Therapeutics by 78.8% during the first quarter. Cubist Systematic Strategies LLC now owns 2,782 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 1,226 shares during the period. Finally, Royal Bank of Canada increased its stake in Celldex Therapeutics by 92.2% during the 2nd quarter. Royal Bank of Canada now owns 5,019 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 2,407 shares during the period.

Celldex Therapeutics Stock Performance

Shares of NASDAQ:CLDX traded up $0.18 on Thursday, hitting $41.97. The company’s stock had a trading volume of 579,320 shares, compared to its average volume of 958,280. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -14.42 and a beta of 1.52. Celldex Therapeutics, Inc. has a 12 month low of $22.11 and a 12 month high of $53.18. The stock’s 50-day moving average is $41.20 and its two-hundred day moving average is $34.38.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. The company had revenue of $4.13 million during the quarter, compared to analyst estimates of $1.20 million. Equities analysts expect that Celldex Therapeutics, Inc. will post -2.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CLDX has been the subject of a number of recent analyst reports. TD Cowen initiated coverage on shares of Celldex Therapeutics in a research report on Wednesday, December 20th. They set an “outperform” rating for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Finally, Guggenheim boosted their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.00.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.